Phase I Vaccination Study Testing the Safety and Reactogenicity of a Recombinant MVA HIV Multiantigen Vaccine (MVA-mBN120B) in HIV-Infected Subjects With CD4 Count greater than 350/microL

Trial Profile

Phase I Vaccination Study Testing the Safety and Reactogenicity of a Recombinant MVA HIV Multiantigen Vaccine (MVA-mBN120B) in HIV-Infected Subjects With CD4 Count greater than 350/microL

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 May 2010

At a glance

  • Drugs MVA-mBN120B (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 19 May 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 19 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top